Christine Chevreau

Active 1992–2024

135
Papers
27,323
Citations
81
h-index
134
i10-index

Citations

Citations per year for Christine Chevreau1956: 1 citations1991: 1 citations1993: 1 citations1995: 2 citations1996: 5 citations1997: 16 citations1998: 13 citations1999: 21 citations2000: 31 citations2001: 22 citations2002: 36 citations2003: 31 citations2004: 37 citations2005: 47 citations2006: 55 citations2007: 121 citations2008: 183 citations2009: 221 citations2010: 224 citations2011: 206 citations2012: 193 citations2013: 192 citations2014: 131 citations2015: 119 citations2016: 138 citations2017: 161 citations2018: 128 citations2019: 542 citations2020: 691 citations2021: 718 citations2022: 658 citations2023: 525 citations2024: 912 citations2025: 371 citations2026: 5 citations1957–1990: no citations, so these years are not shown1992: no citations, so this year is not shown1994: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,274 citing papers, 23.5% of this breakdownFrance: 783 citing papers, 8.1% of this breakdownChina: 729 citing papers, 7.5% of this breakdownItaly: 684 citing papers, 7.1% of this breakdownUnited Kingdom: 597 citing papers, 6.2% of this breakdownGermany: 542 citing papers, 5.6% of this breakdownNetherlands: 387 citing papers, 4% of this breakdownCanada: 372 citing papers, 3.9% of this breakdownSpain: 339 citing papers, 3.5% of this breakdownJapan: 290 citing papers, 3% of this breakdownSwitzerland: 230 citing papers, 2.4% of this breakdownBelgium: 204 citing papers, 2.1% of this breakdown
0%23.5%Other 23.1%

Fields

  • Medicine81.1%
  • Biochemistry, Genetics and Molecular Biology12%
  • Immunology and Microbiology4.2%
  • Neuroscience0.4%
  • Engineering0.4%
  • Materials Science0.4%
  • Other1.5%

Topics

  • Renal cell carcinoma treatment8.5%
  • Sarcoma Diagnosis and Treatment6.4%
  • Cancer Immunotherapy and Biomarkers5.4%
  • Bladder and Urothelial Cancer Treatments4%
  • Cancer Genomics and Diagnostics2.6%
  • Renal and related cancers2.6%
  • Other70.5%

Coauthors

All papers

Open in search
  1. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jaqueline Willemann-Rogerio, David I. Quinn, Thomas Powles - New England Journal of Medicine 2021 cited by 746

  2. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 cited by 263

  3. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli and 127 more - The Lancet Oncology 2020 cited by 498

  4. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Piotr Sawrycki, Naomi B. Haas, Howard Gurney, Mauricio Mahave, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Christine Chevreau, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Delphine Topart, Stéphane Oudard, Evgeniy Kopyltsov, H. Hammers, David I. Quinn, Ajjai Alva, Juliana de Menezes, Adriano Gonçalves e Silva, Eric Winquist, Alketa Hamzaj, Giuseppe Procopio, Boguslawa Karaszewska, Ewa M. Nowakowska-Zajdel, B. Yа. Alekseev, Rustem Gafanov, А. А. Измайлов, Andrey Semenov, S. G. Afanasyev, Oleg Lipatov, T.B. Powles, Sandy Srinivas, David F. McDermott, Samith T. Kochuparambil, Ian D. Davis, Katriina Peltola, Roberto Sabbatini, Jinsoo Chung, М. I. Shkolnik, В. Б. Матвеев, P. Gajate Borau, Steven McCune, Thomas E. Hutson, Alejandro Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, Peter J. Boström, Brigitte Laguerre, Consuelo Buttigliero, Ugo De Giorgi, Eugeniy A. Fomin, Yousef Zakharia, Clara Hwang, Eric A. Singer, Jeffrey T. Yorio, David Waterhouse, Rubén Dario Kowalyszyn, Margarita Sonia Alfie, Eduardo Yañez Ruiz, Tomáš Büchler, Krista Kankaanranta, G. Ferretti, Go Kimura, Kazuo Nishimura, Naoya Masumori, Satoshi Tamada, Haruaki Kato, Hiroshi Kitamura, Iwona Danielewicz and 133 more - The Lancet Oncology 2022 cited by 278

  5. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 940

  6. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

    Authors: , , , , , , , , , , , , , , - JAMA Oncology 2017 cited by 394

  7. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nizar M. Tannir - Cancer 2020 cited by 337

  8. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2007 cited by 4,784

  9. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 cited by 322

  10. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Valérie Lebrun-Ly, Elsa Kalbacher, Florence Duffaud, Corinne Delcambre, Emmanuelle Bompas, Olivier Collard, Nicolás Isambert, Cécile Guillemet, P Soulié, María Rios, Esma Saâda-Bouzid - The Lancet Oncology 2022 cited by 125

  11. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial

    Authors: , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 193

  12. Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Cancer Research 2023 cited by 88

  13. Surgery in reference centers improves survival of sarcoma patients: a nationwide study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Emmanuelle Bompas, Christine Chevreau, Florence Duffaud, María Rios, Christophe Perrin, Nelly Firmin, François Bertucci, C. Le Péchoux, François Le Loarer, Olivier Collard, Marie Karanian, Mehdi Brahmi, Armelle Dufresne, Aurélien Dupré, Françoise Ducimetière, Antoine Giraud, David Pérol, Maud Toulmonde, Isabelle Ray‐Coquard, Antoîne Italiano, Axel Le Cesne, Nicolas Penel, Sylvie Bonvalot - Annals of Oncology 2019 cited by 332

  14. Improved survival using specialized multidisciplinary board in sarcoma patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2017 cited by 362

  15. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2018 cited by 316

  16. Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2008 cited by 693

  17. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jean Marc Tourani, Camille Serrate, A. Colau, Carolina Saldana, Alexandre de la Taille, Thi Hong Lieu Nguyen, F. Kleinclauss, Yohan LORIOT, Jacques Irani, J.C. Eymard, S. Larré, Olivier Huillard, Marc Zerbib, Frédéric Rolland, J. Rigaud, Nadine Houédé, S. Droupy, Georgina MALOUF, Morgan Rouprêt, S. Vieillot, N. Letang, T. L'Haridon, N. Gaschignard, Werner Hilgers, Jean Louis DAVIN - The Lancet Oncology 2023 cited by 96

  18. Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2003 cited by 840

  19. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2021 cited by 128

  20. Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cheng‐Ming Sun, Virginie Verkarre, Guillaume Lacroix, Marco Moreira, Maxime Meylan, Antoine Bougoüin, Letuan Phan, Christelle Thibault-Carpentier, Jessica Zucman‐Rossi, Wolf H. Fridman, Catherine Sautès‐Fridman, Stéphane Oudard - The Lancet Oncology 2022 cited by 136

  21. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

    Authors: , , , , , , , , , , , , , , - The Lancet 2007 cited by 2,223

  22. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 cited by 279

  23. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders

    Authors: , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2018 cited by 98

  24. CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment

    Authors: , , , , , , , , , , , , , , - European Journal of Cancer 2020 cited by 94